Cardiff Oncology Inc
CRDF2.920USD
+0.350+13.62%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
195.92MMarket Cap
LossP/E TTM
More Details of Cardiff Oncology Inc Company
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small-molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has other ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
Cardiff Oncology Inc Info
Ticker SymbolCRDF
Company nameCardiff Oncology Inc
IPO dateJul 27, 2004
CEOErlander (Mark)
Number of employees32
Security typeOrdinary Share
Fiscal year-endJul 27
Address11055 Flintkote Ave
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121
Phone18589527570
Websitehttps://cardiffoncology.com/
Ticker SymbolCRDF
IPO dateJul 27, 2004
CEOErlander (Mark)
Company Executives of Cardiff Oncology Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Gary William Pace, Ph.D.
Dr. Gary William Pace, Ph.D.
Independent Director
Independent Director
1.33M
+26.05%
Ms. Lale White
Ms. Lale White
Independent Director
Independent Director
113.79K
--
Mr. James E. (Jamie) Levine
Mr. James E. (Jamie) Levine
Chief Financial Officer
Chief Financial Officer
67.72K
+12.86%
Dr. Rodney S. Markin, M.D., Ph.D.
Dr. Rodney S. Markin, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
31.06K
--
Dr. James O. Armitage, M.D.
Dr. James O. Armitage, M.D.
Independent Director
Independent Director
27.49K
--
Dr. Mark Erlander, Ph.D.
Dr. Mark Erlander, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
24.48K
--
Dr. Renee P. Tannenbaum, Pharm.D.
Dr. Renee P. Tannenbaum, Pharm.D.
Independent Director
Independent Director
20.00K
--
Dr. Tod Smeal, Ph.D.
Dr. Tod Smeal, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Mani Mohindru, Ph.D.
Dr. Mani Mohindru, Ph.D.
Independent Director
Independent Director
--
--
Dr. Roger Sidhu, M.D.
Dr. Roger Sidhu, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Gary William Pace, Ph.D.
Dr. Gary William Pace, Ph.D.
Independent Director
Independent Director
1.33M
+26.05%
Ms. Lale White
Ms. Lale White
Independent Director
Independent Director
113.79K
--
Mr. James E. (Jamie) Levine
Mr. James E. (Jamie) Levine
Chief Financial Officer
Chief Financial Officer
67.72K
+12.86%
Dr. Rodney S. Markin, M.D., Ph.D.
Dr. Rodney S. Markin, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
31.06K
--
Dr. James O. Armitage, M.D.
Dr. James O. Armitage, M.D.
Independent Director
Independent Director
27.49K
--
Dr. Mark Erlander, Ph.D.
Dr. Mark Erlander, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
24.48K
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
121.00K
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
5.40%
The Vanguard Group, Inc.
5.33%
Laurion Capital Management LP
3.66%
Pfizer Inc
3.58%
William Blair & Company, L.L.C. (Research)
3.29%
Other
78.75%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
5.40%
The Vanguard Group, Inc.
5.33%
Laurion Capital Management LP
3.66%
Pfizer Inc
3.58%
William Blair & Company, L.L.C. (Research)
3.29%
Other
78.75%
Shareholder Types
Shareholders
Proportion
Investment Advisor
17.94%
Investment Advisor/Hedge Fund
6.45%
Research Firm
4.59%
Hedge Fund
4.52%
Corporation
3.58%
Individual Investor
2.40%
Bank and Trust
0.53%
Venture Capital
0.23%
Pension Fund
0.01%
Other
59.76%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
223
23.08M
52.89%
-126.00
2025Q3
226
23.08M
53.74%
-3.50M
2025Q2
215
26.57M
49.56%
-3.56M
2025Q1
202
30.13M
41.18%
+2.73M
2024Q4
189
25.87M
23.45%
+12.69M
2024Q3
166
14.15M
36.04%
-339.38K
2024Q2
167
14.58M
27.53%
+4.43M
2024Q1
180
10.17M
31.18%
-3.76M
2023Q4
174
6.87M
38.04%
-1.17M
2023Q3
187
8.04M
39.68%
-539.21K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
3.59M
5.39%
+45.37K
+1.28%
Jun 30, 2025
The Vanguard Group, Inc.
3.73M
5.6%
+612.97K
+19.68%
Jun 30, 2025
Laurion Capital Management LP
1.80M
2.7%
+881.07K
+96.16%
Jun 30, 2025
Pfizer Inc
2.41M
3.63%
--
--
Jun 30, 2025
William Blair & Company, L.L.C. (Research)
2.52M
3.79%
+772.84K
+44.13%
Jun 30, 2025
Acorn Capital Advisors, LLC
1.41M
2.12%
-33.54K
-2.33%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.50M
2.25%
+104.41K
+7.49%
Jun 30, 2025
Pace (Gary William)
1.33M
2%
+275.00K
+26.05%
Jul 30, 2025
State Street Investment Management (US)
1.13M
1.69%
+186.24K
+19.81%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.03%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
Vanguard US Momentum Factor ETF
0%
Invesco Russell 2000 Dynamic Multifactor ETF
0%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Growth ETF
0%
Avantis US Small Cap Equity ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.03%
Global X Russell 2000 ETF
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
Vanguard US Momentum Factor ETF
Proportion0%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Cardiff Oncology Inc?
The top five shareholders of Cardiff Oncology Inc are:
BlackRock Institutional Trust Company, N.A. holds 3.59M shares, accounting for 5.39% of the total shares.
The Vanguard Group, Inc. holds 3.73M shares, accounting for 5.60% of the total shares.
Laurion Capital Management LP holds 1.80M shares, accounting for 2.70% of the total shares.
Pfizer Inc holds 2.41M shares, accounting for 3.63% of the total shares.
William Blair & Company, L.L.C. (Research) holds 2.52M shares, accounting for 3.79% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.59M shares, accounting for 5.39% of the total shares.
The Vanguard Group, Inc. holds 3.73M shares, accounting for 5.60% of the total shares.
Laurion Capital Management LP holds 1.80M shares, accounting for 2.70% of the total shares.
Pfizer Inc holds 2.41M shares, accounting for 3.63% of the total shares.
William Blair & Company, L.L.C. (Research) holds 2.52M shares, accounting for 3.79% of the total shares.
What are the top three shareholder types of Cardiff Oncology Inc?
The top three shareholder types of Cardiff Oncology Inc are:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Laurion Capital Management LP
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Laurion Capital Management LP
How many institutions hold shares of Cardiff Oncology Inc (CRDF)?
As of 2025Q4, 223 institutions hold shares of Cardiff Oncology Inc, with a combined market value of approximately 23.08M, accounting for 52.89% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.86%.
What is the biggest source of revenue for Cardiff Oncology Inc?
In FY2025Q2, the -- business generated the highest revenue for Cardiff Oncology Inc, amounting to -- and accounting for --% of total revenue.
